human hepatocytes
Phase 1Small molecule
human hepatocytes is one of 12 small molecule programs targeting Liver Failure. It is currently in Phase 1.
1
Indications
2
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Liver Failure
#DrugCompanyPhaseTrials
1Cancidas
FFresenius Kabi Oncology Ltd.
Approved
Lucemyra
BBioCorRx Pharmaceuticals Inc
Approved
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Glypressin
MMallinckrodt
Approved
Trental
VValidus Pharmaceuticals
Approved
Octreotide
Johnson & JohnsonPhase 3
Chibroxin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Soticlestat
TakedaPhase 1
Conserved Therapy
SSun Yat-sen University
Phase 2
Prograf
VVeloxis Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for human hepatocytes. EMBL-EBI & Wellcome Sanger Institute.
- [4]